2022
Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study
Stavrou E, Qiu J, Zafar A, Tramontano AC, Isakoff S, Winer E, Schrag D, Manz C. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. JCO Oncology Practice 2022, 18: e1447-e1453. PMID: 35671420, PMCID: PMC9509057, DOI: 10.1200/op.22.00072.Peer-Reviewed Original ResearchConceptsBreast cancer careCancer carePercent of respondentsCancer CenterDana-Farber Cancer InstituteBreast cancer followMedical oncologist's perspectiveAcademic cancer centerPatient-physician communicationUse of telemedicineMost respondentsTM visitsCancer followRoutine followOncologist's perspectiveOncology visitsPatient adherenceOncology cliniciansClinicians' perceptionsFace visitsBreast cliniciansCancer InstituteSecond opinion consultationPatient carePatient records
2010
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. Journal Of Clinical Oncology 2010, 28: 2418-2422. PMID: 20368559, PMCID: PMC2881723, DOI: 10.1200/jco.2009.26.4671.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAge FactorsAgedAged, 80 and overAntimetabolites, AntineoplasticBreast NeoplasmsCanadaCapecitabineChemotherapy, AdjuvantDeoxycytidineDrug Administration ScheduleDrug MonitoringFemaleFluorouracilHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMastectomyMedication AdherenceMicro-Electrical-Mechanical SystemsNeoplasm StagingRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsEarly-stage breast cancerBreast cancerCALGB 49907Oral chemotherapyClinical trialsOlder womenPatients age 65 yearsOral adjuvant chemotherapyPill bottle openingsNode-negative diseaseHormone receptor statusRelapse-free survivalRandomized clinical trialsAge 65 yearsMulticenter clinical trialNumber of dosesPercent of participantsLogistic regression modelsAdjuvant chemotherapyProtocol therapyOral therapyStandard chemotherapyMedian ageReceptor statusPatient adherence
2002
Adherence to Therapy With Oral Antineoplastic Agents
Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to Therapy With Oral Antineoplastic Agents. Journal Of The National Cancer Institute 2002, 94: 652-661. PMID: 11983753, DOI: 10.1093/jnci/94.9.652.Peer-Reviewed Original ResearchConceptsOral antineoplastic agentsAntineoplastic agentsOral antineoplastic therapyOral anticancer agentsAssessment of adherenceStudy of adherencePrediction of adherenceImplementation of interventionsChemotherapy recommendationsOral medicationsPrescribed regimensClinical outcomesPatient adherencePediatric populationAdherence ratesPoor adherenceAntineoplastic therapyAdherence issuesClinical trialsCancer preventionPhysician's officeAdherence behaviorAvailable evidenceAdherenceCertain populations